Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
Shared Decisionmaking Called For In PSA Screening For Ages 55-69
ACCP Publishes Guidelines Recommending Low-Dose CT
Study: Routine CT Not Needed In Detecting DLBCL Remissions
Surveillance Following Surgery Sufficient in Stage I Seminoma
Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
NCI CTEP Approved Trials For the Month of May
FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
Trending Stories
- Karen Knudsen to leave ACS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies - Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Tumors are able to form with no DNA mutations, fly study shows
- From clinician scientist to nonprofit CEO